JP2001521504A - メタロプロテイナーゼ阻害薬、それらを含有する薬剤組成物および薬剤としてのそれらの使用 - Google Patents
メタロプロテイナーゼ阻害薬、それらを含有する薬剤組成物および薬剤としてのそれらの使用Info
- Publication number
- JP2001521504A JP2001521504A JP54194598A JP54194598A JP2001521504A JP 2001521504 A JP2001521504 A JP 2001521504A JP 54194598 A JP54194598 A JP 54194598A JP 54194598 A JP54194598 A JP 54194598A JP 2001521504 A JP2001521504 A JP 2001521504A
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- group
- benzenesulfonyl
- hydroxy
- butanamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
- C07D213/643—2-Phenoxypyridines; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/32—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/32—Sulfur atoms
- C07D213/34—Sulfur atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/68—One oxygen atom attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.式Iの化合物: (式中、 YはOまたはSであり; Arはアリール基またはヘテロアリール基であり; Rは水素、アルキル基、シクロアルキル基、ヘテロシクロアルキル基、アリー ル基、ヘテロアリール基、または−C(O)R1であり、 ここでR1は水素、アルキル基、シクロアルキル基、ヘテロシクロアルキル 基、アリール基、ヘテロアリール基またはNR2R2であり、ここでR2およびR2 は独立して水素、アルキル基、シクロアルキル基、ヘテロシクロアルキル基、ア リール基またはヘテロアリール基であり; Xは−NH−OHまたは−OHである) またはその薬剤学的に許容しうるプロドラッグ、塩もしくは溶媒和物。 2.Arが、Y部分に対しパラ位において適切な置換基で置換されたアリール 基である、請求項1記載の化合物またはその薬剤学的に許容しうるプロドラッグ 、塩もしくは溶媒和物。 3.適切な置換基がハロゲン、アルキル基、O−アルキル基、アリール基、ヘ テロアリール基、またはS−アルキル基である、請求項2記載の化合物またはそ の薬剤学的に許容しうるプロドラッグ、塩もしくは溶媒和物。 4.Rがアルキル基である、請求項1記載の化合物またはその薬剤学的に許容 しうるプロドラッグ、塩もしくは溶媒和物。 5.Rがアルキル基−(CH3)2−S−アルキルである、請求項4記載の化合 物またはその薬剤学的に許容しうるプロドラッグ、塩もしくは溶媒和物。 6.Rがアルキル基−C(CH3)2−S−CH2−ヘテロアリールである、請 求項5記載の化合物またはその薬剤学的に許容しうるプロドラッグ、塩もしくは 溶媒和物。 7.YがOである、請求項1記載の化合物。 8.YがSである、請求項1記載の化合物。 9.化合物が式Ia: を有する、請求項1記載の化合物またはその薬剤学的に許容しうるプロドラッグ 、塩もしくは溶媒和物。 10.化合物が下記のものから選択される、請求項1記載の化合物: 2(S)−N−ヒドロキシ−3,3−ジメチル−2−[(4−(4−フルオロ フェノキシ)ベンゼンスルホニル)アミノ]ブタンアミド、 2(S)−N−ヒドロキシ−3,3−ジメチル−2−[(4−(4−クロロフ ェノキシ)ベンゼンスルホニル)アミノ]ブタンアミド、 2(S)−N−ヒドロキシ−3−メチル−3−(ピリド−2−イル)メチルス ルファニル−2−[(4−(4−フルオロフェノキシ)ベンゼンスルホニル)アミ ノ]ブタンアミド、 2(S)−N−ヒドロキシ−3−メチル−3−(ピリド−2−イル)メチルス ルファニル−2−[(4−(4−ブロモフェノキシ)ベンゼンスルホニル)アミノ ]ブタンアミド、 N−[4−(4−ブロモフェノキシ)ベンゼンスルホニル]−S−[(1−ベ ンジル−1H−イミダゾール−2−イル)メチル]−D−ペニシラミン、 N−[4−(4−ヨードフェノキシ)ベンゼンスルホニル]−S−[(ピリド −2−イル)メチル]−D−ペニシラミン、 2(S)−N−ヒドロキシ−3−メチル−3−(ピリド−2−イル)メチルス ルファニル−2−[(4−(4−ヨードフェノキシ)ベンゼンスルホニル)アミノ ]ブタンアミド、 N−[4−(4−ブロモフェノキシ)ベンゼンスルホニル]−S−[(5−メ チルイソオキサゾール−3−イル)メチル]−D−ペニシラミン、 2(S)−N−ヒドロキシ−3−メチル−3−(5−メチルイソオキサゾール −3−イル)メチルスルファニル−2−[(4−(4−フルオロフェノキシ)ベ ンゼンスルホニル)アミノ]ブタンアミド、 2(S)−N−ヒドロキシ−3−メチル−3−(5−メチルイソオキサゾール −3−イル)メチルスルファニル−2−[(4−(4−ブロモフェノキシ)ベン ゼンスルホニル)アミノ]ブタンアミド、 2(S)−N−ヒドロキシ−3−メチル−3−(ピリド−2−イル)メチルス ルファニル−2−[(4−(4−メチルフェノキシ)ベンゼンスルホニル)アミノ ]ブタンアミド、 2(S)−N−ヒドロキシ−3−メチル−3−(5−メチルイソオキサゾール −3−イル)メチルスルファニル−2−[(4−(ピリド−4−イルオキシ)ベ ンゼンスルホニル)アミノ]ブタンアミド、 2(S)−N−ヒドロキシ−3−メチル−3−(5−メチルイソオキサゾール −3−イル)メチルスルファニル−2−[(4−{(ピリド−4−イル)スルファ ニル}ベンゼンスルホニル)アミノ]ブタンアミド、 2(S)−N−ヒドロキシ−3−メチル−3−(1H−イミダゾール−4−イ ル)メチルスルファニル−2−[(4−(4−ブロモフェノキシ)ベンゼンスル ホニル)アミノ]ブタンアミド、 2(S)−N−ヒドロキシ−3−メチル−3−(1−メチル−1H−イミダゾ ール−2−イル)メチルスルファニル−2−[(4−(4−ブロモフェノキシ) ベンゼンスルホニル)アミノ]ブタンアミド、 2(S)−N−ヒドロキシ−3−メチル−3−(1−メチル−1H−イミダゾ ール−4−イル)メチルスルファニル−2−[(4−(4−ブロモフェノキシ) ベンゼンスルホニル)アミノ]ブタンアミド、 2(S)−N−ヒドロキシ−3−メチル−3−(4−メチル−4H−[1,2 , 4]−トリアゾール−3−イル)メチルスルファニル−2−[(4−(4−ブロ モフェノキシ)ベンゼンスルホニル)アミノ]ブタンアミド、 2(S)−N−ヒドロキシ−3−メチル−3−(1−メチル−4H−[1,2 ,4]−トリアゾール−3−イル)メチルスルファニル−2−[(4−(4−ブ ロモフェノキシ)ベンゼンスルホニル)アミノ]ブタンアミド、 2(S)−N−ヒドロキシ−3−メチル−3−メチルスルファニル−2−[( 4−(4−クロロフェノキシ)ベンゼンスルホニル)アミノ]ブタンアミド; ならびにその薬剤学的に許容しうるプロドラッグ、塩類および溶媒和物。 11.(a)療法上有効な量の請求項1記載の化合物、またはその薬剤学的に許 容しうるプロドラッグ、塩もしくは溶媒和物;および (b)薬剤学的に許容しうるキャリヤー、希釈剤、ビヒクルまたは賦形剤を含 む薬剤組成物。 12.メタロプロテイナーゼ活性により仲介される哺乳動物の疾病状態を処置 する方法であって、その必要がある哺乳動物に療法上有効な量の請求項1記載の 化合物、またはその薬剤学的に許容しうるプロドラッグ、塩もしくは溶媒和物を 投与することを含む方法。 13.哺乳動物の疾病状態が腫瘍の増殖、侵入または転移である、請求項12 記載の方法。 14.哺乳動物の疾病状態が骨関節症、慢性関節リウマチ、骨粗しょう症、歯 周炎または歯肉炎である、請求項12記載の方法。 15.哺乳動物の疾病状態が慢性皮膚創傷、角膜潰瘍形成または変性性皮膚障 害である、請求項12記載の方法。 16.哺乳動物の疾病状態が多発性硬化症または発作である、請求項12記載 の方法。 17.哺乳動物の疾病状態がアテローム性動脈硬化症、糸球体疾患またはアル ツハイマー病である、請求項12記載の方法。 18.哺乳動物の疾病状態が望ましくない血管形成を特色とする、請求項12 記載の方法。 19.哺乳動物の疾病状態が糖尿病性網膜症、黄斑変性、血管線維腫または血 管腫である、請求項12記載の方法。 20.哺乳動物の疾病状態がマトリックスメタロプロテイナーゼ活性により仲 介される、請求項12記載の方法。 21.哺乳動物の疾病状態がTNF−α変換酵素活性により仲介される、請求 項12記載の方法。 22.少なくとも1種類のメタロプロテイナーゼの活性を阻害する方法であっ て、その少なくとも1種類のメタロプロテイナーゼを有効量の請求項1記載の化 合物、またはその薬剤学的に許容しうるプロドラッグ、塩もしくは溶媒和物と接 触させることを含む方法。 23.少なくとも1種類のメタロプロテイナーゼがマトリックスメタロプロテ イナーゼである、請求項22記載の方法。 24.少なくとも1種類のメタロプロテイナーゼがTNF−α変換酵素である 、請求項22記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US82531897A | 1997-04-01 | 1997-04-01 | |
US08/825,318 | 1997-04-01 | ||
PCT/US1998/006365 WO1998043963A1 (en) | 1997-04-01 | 1998-03-31 | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2001521504A true JP2001521504A (ja) | 2001-11-06 |
JP2001521504A5 JP2001521504A5 (ja) | 2005-11-24 |
Family
ID=25243697
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP54194598A Ceased JP2001521504A (ja) | 1997-04-01 | 1998-03-31 | メタロプロテイナーゼ阻害薬、それらを含有する薬剤組成物および薬剤としてのそれらの使用 |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP0973748A1 (ja) |
JP (1) | JP2001521504A (ja) |
KR (1) | KR20010005940A (ja) |
AU (1) | AU747280B2 (ja) |
BR (1) | BR9809062A (ja) |
CA (1) | CA2285372A1 (ja) |
NZ (1) | NZ338082A (ja) |
WO (1) | WO1998043963A1 (ja) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6423729B1 (en) * | 1997-07-22 | 2002-07-23 | Shionogi & Co., Ltd. | Therapeutic or prophylactic agent for glomerulopathy |
JP2001513484A (ja) * | 1997-07-31 | 2001-09-04 | ザ プロクター アンド ギャンブル カンパニー | 非環式メタロプロテアーゼ阻害剤 |
IL127496A0 (en) * | 1997-12-19 | 1999-10-28 | Pfizer Prod Inc | The use of MMP inhibitors for the treatment of ocular angiogenesis |
HUP0101176A3 (en) | 1998-02-04 | 2002-06-28 | Novartis Ag | Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases, process for their preparation and pharmaceutical compositions containing them |
US6410580B1 (en) | 1998-02-04 | 2002-06-25 | Novartis Ag | Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases |
US6075136A (en) * | 1998-02-17 | 2000-06-13 | Incyte Pharmaceuticals, Inc. | Prostate-associated serine protease |
US6492394B1 (en) | 1998-12-22 | 2002-12-10 | Syntex (U.S.A.) Llc | Sulfonamide hydroxamates |
US6313123B1 (en) | 1999-01-27 | 2001-11-06 | American Cyanamid Company | Acetylenic sulfonamide thiol tace inhibitors |
US6946473B2 (en) | 1999-01-27 | 2005-09-20 | Wyeth Holdings Corporation | Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors |
US6753337B2 (en) | 1999-01-27 | 2004-06-22 | Wyeth Holdings Corporation | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors |
US6277885B1 (en) | 1999-01-27 | 2001-08-21 | American Cyanamid Company | Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors |
US6200996B1 (en) | 1999-01-27 | 2001-03-13 | American Cyanamid Company | Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors |
US6225311B1 (en) | 1999-01-27 | 2001-05-01 | American Cyanamid Company | Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors |
US6762178B2 (en) | 1999-01-27 | 2004-07-13 | Wyeth Holdings Corporation | Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors |
BR0007784A (pt) | 1999-01-27 | 2002-02-05 | American Cyanamid Co | Composto, método para inibir mudanças patológicas mediadas pela enzima que converte o tnf-alfa (tace) em um mamìfero, composição farmacêutica, e, processo para preparar um composto |
US6326516B1 (en) | 1999-01-27 | 2001-12-04 | American Cyanamid Company | Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors |
US6340691B1 (en) | 1999-01-27 | 2002-01-22 | American Cyanamid Company | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors |
BR0009244A (pt) | 1999-03-03 | 2002-04-16 | Procter & Gamble | Inibidores de metaloprotease di-hétero substituìdos |
HUP0202199A2 (en) | 1999-03-03 | 2002-10-28 | Procter & Gamble | Alkenyl- and alkynyl-containing metalloprotease inhibitors |
US6696456B1 (en) * | 1999-10-14 | 2004-02-24 | The Procter & Gamble Company | Beta disubstituted metalloprotease inhibitors |
JP2005507937A (ja) | 2001-11-01 | 2005-03-24 | ワイス・ホールディングズ・コーポレイション | マトリックスメタロプロテイナーゼおよびtace阻害剤としてのアレンアリールスルホンアミドヒドロキサム酸 |
WO2003055851A1 (fr) | 2001-12-27 | 2003-07-10 | Sumitomo Pharmaceuticals Company, Limited | Derives d'acide hydroxamique et inhibiteur des mmp contenant ces derniers en tant que substance active |
EP1511488B1 (en) * | 2002-06-12 | 2013-05-22 | Symphony Evolution, Inc. | Human adam-10 inhibitors |
US7199155B2 (en) | 2002-12-23 | 2007-04-03 | Wyeth Holdings Corporation | Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors |
CA2671524A1 (en) * | 2006-12-01 | 2008-06-12 | Loma Linda University Medical Center | Inhibition of brain enzymes involved in cerebral amyloid angiopathy and macular degeneration |
BR112021006407A8 (pt) | 2018-10-04 | 2022-12-06 | Inst Nat Sante Rech Med | uso de inibidores do egfr para ceratodermas |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2303850B (en) * | 1994-06-22 | 1998-06-10 | British Biotech Pharm | Metalloproteinase inhibitors |
US5863949A (en) * | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
ATE226936T1 (de) * | 1995-08-08 | 2002-11-15 | Ono Pharmaceutical Co | Hydroxamsäurederivate verwendbar zur hemmung von gelatinase |
US6153757A (en) * | 1995-12-08 | 2000-11-28 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors and intermediates useful for their preparation |
ATE359264T1 (de) * | 1996-01-23 | 2007-05-15 | Shionogi & Co | Sulfonierte aminosäurederivate und metalloproteinase-inhibitoren, die diese enthalten |
-
1998
- 1998-03-31 EP EP98914379A patent/EP0973748A1/en not_active Withdrawn
- 1998-03-31 WO PCT/US1998/006365 patent/WO1998043963A1/en not_active Application Discontinuation
- 1998-03-31 JP JP54194598A patent/JP2001521504A/ja not_active Ceased
- 1998-03-31 NZ NZ338082A patent/NZ338082A/en unknown
- 1998-03-31 KR KR1019997009017A patent/KR20010005940A/ko not_active Application Discontinuation
- 1998-03-31 AU AU68744/98A patent/AU747280B2/en not_active Ceased
- 1998-03-31 BR BR9809062-3A patent/BR9809062A/pt not_active IP Right Cessation
- 1998-03-31 CA CA002285372A patent/CA2285372A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO1998043963A1 (en) | 1998-10-08 |
EP0973748A1 (en) | 2000-01-26 |
AU747280B2 (en) | 2002-05-09 |
KR20010005940A (ko) | 2001-01-15 |
AU6874498A (en) | 1998-10-22 |
BR9809062A (pt) | 2000-08-01 |
CA2285372A1 (en) | 1998-10-08 |
NZ338082A (en) | 2000-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2001521504A (ja) | メタロプロテイナーゼ阻害薬、それらを含有する薬剤組成物および薬剤としてのそれらの使用 | |
USH1992H1 (en) | Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their pharmaceutical uses | |
RU2175316C2 (ru) | Арил-s(о)nзамещенные карбоновые/гидроксамовые кислоты и способ их получения | |
KR101762574B1 (ko) | 플라즈미노겐 액티베이터 인히비터-1 저해제 | |
KR100587546B1 (ko) | 프로테아제 억제제인 아미노구아니딘 및 알콕시구아니딘 | |
US5985900A (en) | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses | |
ES2236829T3 (es) | Acidos beta-sulfonil hidroxamicos como inhibidores de las metaloproteinas de la matriz. | |
EA005369B1 (ru) | Новые соединения и композиции в качестве ингибиторов протеазы | |
JP2001508796A (ja) | トロンビン阻害薬 | |
JP2003500385A (ja) | Xa因子阻害剤 | |
AU7703300A (en) | Compounds and pharmaceutical compositions as cathepsin s inhibitors | |
JP2010248209A (ja) | ニトロソ化およびニトロシル化された非ステロイド抗炎症性化合物、組成物および使用方法 | |
CZ292942B6 (cs) | Derivát (N-hydroxykarbamoyl)-1-(4-fenoxy)benzensulfonylu | |
JP2002536432A (ja) | 第Xa因子の阻害剤 | |
JP2000502710A (ja) | 置換n―[(アミノイミノメチル又はアミノメチル)フェニル]プロピルアミド | |
EA034436B1 (ru) | Гетероарильные производные бутановой кислоты в качестве ингибиторов lta4h | |
JP2004533464A (ja) | ヘテロアリールスルホニル側鎖を有するアントラニル酸アミド、その製造方法、その医薬または診断助剤としての使用、およびこの化合物を含有する医薬製剤 | |
EP2141147A1 (en) | Ornithine derivative | |
JPWO2005026127A1 (ja) | プラスミノゲンアクチベータインヒビター−1阻害剤 | |
JP2002538136A (ja) | アルケニルおよびアルキニル含有メタロプロテアーゼ阻害剤 | |
JP2000514043A (ja) | マトリックスメタロプロテイナーゼ・インヒビター | |
JP2003505367A (ja) | マトリックスメタロプロテイナーゼ阻害剤としての3−アリールスルホニル−2−(置換メチル)プロパン酸誘導体 | |
JP2005539005A (ja) | ヘパラナーゼ阻害物質としてのフランチアゾール誘導体 | |
US8729066B2 (en) | 1,2- bis-sulfonamide derivatives as chemokine receptor modulators | |
CA2866078C (en) | Benzofuran-2-sulfonamide derivatives as chemokine receptor modulators |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050330 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050330 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080805 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20081229 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090224 |